Staphylococcus aureus. The persistent pathogen (second of two parts).
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000032:analysis; D000942:Antigens, Bacterial / Q000032:analysis; D001427:Bacterial Toxins / Q000096:biosynthesis; D001769:Blood / Q000382:microbiology; D002353:Carrier State / Q000188:drug therapy; D004352:Drug Resistance, Microbial; D006801:Humans; D009666:Nose / Q000382:microbiology; D012293:Rifampin / Q000627:therapeutic use; D018805:Sepsis / Q000175:diagnosis; D012772:Shock, Septic / Q000209:etiology; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control; D013211:Staphylococcus aureus / Q000302:isolation & purification / Q000378:metabolism / Q000472:pathogenicity; D013262:Stevens-Johnson Syndrome / Q000209:etiology; D013682:Teichoic Acids / Q000276:immunology
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D013682:Teichoic Acids; D012293:Rifampin